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Background: Goal-directed fluid therapy (GDFT) has been shown to reduce complications and hospital length of
stay following major surgery. However, there has been no assessment regarding its use in clinical practice.
Methods: An electronic survey was administered to randomly selected anaesthetists from the United Kingdom
(UK, n = 2000) and the United States of America (USA, n = 2000), and 500 anaesthetists from Australia/New Zealand
(AUS/NZ). Preferences, clinical use and attitudes towards GDFT were investigated. Results were collated to examine
regional differences.
Results: The response rates from the UK (n = 708) and AUS/NZ (n = 180) were 35%, and 36% respectively. The
response rate from the USA was very low (n = 178; 9%). GDFT use was significantly more common in the UK than in
AUS/NZ (p < 0.01). The Oesophageal Doppler Monitor was the most preferred instrument in the UK (n = 362; h76%)
with no clear preferences in other regions. GDFT was most commonly utilised in major abdominal surgery and for
patients with significant comorbidities. The commonest reasons stated for not using GDFT were either lack of
availability of monitoring tools (AUS/NZ: 57 (70%); UK: 94 (64%)) or a lack of experience with instruments (AUS/NZ:
43 (53%); UK: 51 (35%)). A subset of respondents (AUS/NZ: 22(27%); UK: 45 (30%)) felt GDFT provided no perceived
benefit. Enthusiasm towards the use of GDFT in the absence of existing barriers was high.
Conclusion: Several hypotheses were generated regarding important differences in the use of GDFT between
anaesthetists from the UK and AUS/NZ. There is significant interest in utilising GDFT in clinical practice and existing
barriers should be addressed.
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Over the last decade, there has been a renewed emphasis
on research investigating perioperative fluid therapy [1,2].
This has been complemented by a surge in research ex-
ploring optimised perioperative care [3-5]. An increasing
body of work has now highlighted the importance of
physiologically-guided, individualised fluid administration
in keeping with the broad principles recommended by
Moore and Shires over 40 years ago [6,7]. This concept is
known as goal–directed fluid therapy (GDFT).* Correspondence: sanketsri@gmail.com
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reproduction in any medium, provided the orGDFT therapy primarily involves the administration of
intravenous fluids to optimise pre-defined, patient-specific
clinical proxies of tissue perfusion [7]. The individual
parameters used to guide therapy are measures of cardio-
vascular function and vary depending on the monitoring
system used [7]. In practice, GDFT involves repeated ad-
ministration of small boluses of intravenous fluids- often
colloids- until a certain target or plateau is reached. A
baseline infusion of crystalloids is typically given.
A number of randomised trials and subsequent meta-
analyses in various surgical settings have shown that
GDFT confers clinical benefits such as decreased post-
operative morbidity and decreased hospital length of
stay as compared to traditional, liberal fluid therapy
[8-14]. This is thought to be on the basis of treatingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Survey questions
Questions Options
Which country do you work in?
What is your place of practice? (choose as many as applicable) Tertiary Hospital/District (Community) Hospital/Private practice




What is your current position? Trainee/Consultant < 5 years/Consultant 5–10 years/Consultant > 10 years
For adult patients having major elective surgery. . .
What is your preferred intraoperative crystalloid fluid? Normal saline/Balanced salt solution/Dextrose saline/No preference
What is your preferred intraoperative colloid fluid? Succinylated gelatin/Tetrastarch/Pentastarch/Hetastarch/Albumin/Nil/No
preference/Other
What is your preferred intraoperative pressor? (please state type)
For adult patients undergoing major elective surgery, do you use
goal-directed fluid therapy?
Always/Sometimes/Never
If you use goal directed fluid therapy sometimes, when? (Choose
as many as applicable)
Major surgery/Patients with significant comorbidities/Particular operations (state
type)/Depending on Instrument availability/Random/Other
If yes, what kind of surgery do you use goal directed fluid
therapy in? (choose as many as applicable)




What are your preferred tools to conduct Goal Directed Fluid
Therapy? (choose up to 3)
ODM/PPV monitors/SVV monitors/LiDCO/PAC/SvO2/PVI
If you never use goal directed fluid therapy, why? (choose as
many as applicable)
Lack of resources/Nil advantage perceived/Too labour intensive/Unsuitable
patients/Lack of experience with instruments
If existing barriers were removed (e.g. lack of resources/training),
would you like to use Goal Directed Fluid Therapy?
Yes/No/Undecided
ODM: Oesophageal Doppler monitor; PPV: Pulse pressure variation; SVV: Stroke volume variation; LiDCO: Lithium dilution coefficient; PAC: Pulmonary artery
catheter; SvO2: Venous oxygen saturations; PVI: Pleth variability index.
Table 2 Respondent characteristics
AUS/NZ UK p-value*
No of responders (%) 180 708
Response rate 36% 35%
Place of practice (%):
Tertiary Hospital District Hospital 122 (69) 360 (51) <0.01
Private Practice 34 (19) 377 (54) <0.01
68 (38) 89 (13) <0.01
Experience (%):
Trainee 2 (1) 168 (24) <0.01
Consultant <5 years 27 (15) 161 (23) 0.02
Consultant 6–10 years 28 (16) 98 (14) 0.63
Consultant >10 years
122 (68) 269 (39) <0.01
*Two-tailed Fisher’s exact test.
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ting a preoperative functional intravascular deficit early in
the intraoperative phase to decrease the post-surgical in-
flammatory response [9-11]. The National Institute for
Health Research and the Health Technology Assessment
committee in the United Kingdom (UK) found in their sys-
tematic review that GDFT using the Oesophageal Doppler
Monitor (ODM) provides clinical benefits in major surgery
and is cost effective [15]. The National Health Service
Centre for Evidence-based Purchasing also concluded
that the cost of the ODM would be offset by the clin-
ical benefits seen [16]. The use of GDFT tools is also
reimbursed in the United States of America (USA) by
the Center for Medicare and Medicaid Services who
have stated that the use of the Oesophageal Doppler
Monitor (ODM) is both “reasonable and necessary” for
operative patients requiring fluid optimisation [17,18].
As a result, a number of guidelines from professional
groups have recommended the use of GDFT in major
surgery in selected cases [19,20].
However, some authors have expressed reservations
regarding the proposed benefits of GDFT for all patients.
The criticisms include a paucity of trials within an opti-
mised perioperative care environment and no comparisonto intraoperative fluid restriction, which is also recognised
as beneficial in a similar cohort of patients [2,14,21,22]. A
recent qualitative review has also outlined several import-
ant unanswered questions in the context of GDFT in colo-
rectal surgery [23]. Moreover, questions persist regarding
the best monitoring system, the ideal intraoperative fluid
Table 3 Intraoperative fluid preferences
AUS/NZ UK
Crystalloid (%) n = 174 n = 692
0.9% Saline 10 (6) 14 (2)
Balanced Salt Solution 162 (93) 662 (96)
Colloid (%)
Succinylated gelatine 43 (24) 292 (42)
Tetrastarch 30 (17) 98 (14)
Pentastarch 29 (16) 50 (7)
Hetastarch 29 (16) 124 (18)
Albumin 14 (8) 1
No preference 26 (15) 98 (14)
Other 8 (4) 29 (4)
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Therefore, there is clinical and academic equipoise regar-
ding the proposed benefits or otherwise of GDFT.
For those in favour of GDFT, the translation of evidence
into practice can be a significant hurdle [25,26]. Clinical
benefits necessitate proven interventions to be suitably
implemented. Selective implementation of interventions
can often fail to replicate the benefits observed in trials
[25]. It is thus important to assess the current practice
and attitudes of clinicians and to identify barriers that may
prevent the implementation of evidence-based practice
[26,27]. Therefore, we conducted a survey of anaesthetists
nationally and internationally to investigate various char-
acteristics regarding GDFT across Australasia, the United
Kingdom (UK) and the USA. Specific aims included exa-
mining the disparity in clinical uptake of GDFT, situations
within which it was used and the preferred tools as well as











Figure 1 Do you use Goal-directed fluid therapy? (Columns from left
Always/Sometimes: USA vs. UK, p = 0.36; USA vs. NZ, p < 0.01; UK vs. NZ, pMethods
Ethical approval was obtained from the Northern X
Regional Ethics Committee (NTX/10/EXP/147). An elec-
tronic survey was created using a commercially available
internet-based service [28]. The survey was administered
electronically to 2000 randomly chosen members of the
Association of Anaesthetists of Great Britain and Ireland
(AAGBI), 2000 randomly chosen members of the American
Society of Anesthesiology (ASA) and to 500 randomly
chosen members of the Australia and New Zealand College
of Anaesthetists (ANZCA) as per the conditions stipulated
by each organisation. Randomisation and survey admitra-
tion was facilitated by the individual member organisations
with respondents remaining anonymous to the investiga-
tors. One reminder was sent to the non-responders 4 weeks
after the first invitation. The questions from the survey are
presented in Table 1. Results were subsequently collated
and the two-tailed Fisher’s exact test was used to assess
categorical outcomes. A p value of less than 0.05 was
considered statistically significant.
Results
The demographic characteristics of respondents and the
response rates are presented in Table 2. The response
rates in the UK and AUS/NZ were 35% and 36% respect-
ively. The response rate in the USA was 9%, thereby
limiting the validity of any deductions from these data.
Amongst responders, the survey completion rate was
high across all three regions (UK: 94%; AUS/NZ: 89%).
The two commonest subspecialty interests were ortho-
paedic surgery (AUS/NZ: 76 (46%); UK: 240 (37%)) and
abdominal surgery (AUS/NZ: 71(43%); UK: 300 (46%)).
Intraoperative fluid preferences are as per Table 3. The
two most favoured pressors in the UK and AUS/NZUK USA
to right respectively: Always; Sometimes; Never).
< 0.01.
Table 5 Preferred tools for goal-directed fluid therapy
Tools (%) AUS/NZ (n = 78) UK (n = 519)
ODM 11 (19) 362 (76)
PPV 26 (45) 97 (20)
SVV 21 (36) 71 (15)
LiDCO 1 (2) 93 (20)
PAC 17 (29) 35 (7)
SvO2 12 (21) 88 (19)
PVI 3 (5) 8 (2)
ODM: Oesophageal doppler monitor; PPV: Pulse pressure variation; SVV: Stroke
volume variation; LiDCO: Lithium dilution coefficient; PAC: Pulmonary artery
catheter; SvO2: Venous oxygen saturation; PVI: Pleth variability index.
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and phenylephrine (UK: 142 (22%); AUS/NZ: 36 (21%)).
The use of GDFT is shown in Figure 1. GDFT use was
significantly more common in the UK as compared to
AUS/NZ (p < 0.01). In AUS/NZ, GDFT was most com-
monly utilised in abdominal surgery (n = 60; 80%),
followed by orthopaedic surgery (n = 27; 36%). In the
UK, GDFT was most commonly utilised in abdominal
surgery (UK: n = 428 (89%)), followed by vascular sur-
gery (UK: n = 146 (30%)).
The situations when GDFT is utilised and preferred
tools to conduct GDFT are shown in Tables 4 and 5 re-
spectively. The commonest reasons stated for not using
GDFT were either lack of availability of monitoring tools
(AUS/NZ: 57 (70%); UK: 94 (64%)) or a lack of experience
with instruments (AUS/NZ:43 (53%); UK: 51 (35%)). A
subset of respondents cited “nil advantage perceived” as
the reason for not using GDFT (AUS/NZ: 22(27%); UK:
45 (30%)). Enthusiasm towards GDFT in the absence of
existing barriers (e.g. lack of equipment or experience) is
shown in Figure 2.
The respondents from the USA indicated a preference
towards GDFT in abdominal surgery (n = 97; 80%) with
similar barriers to GDFTas described in other regions such
as lack of availability of tools (n = 19; 59%), lack of experi-
ence (n = 13; 40%) and nil perceived advantage (n = 13;
40%). The most favoured pressor in the USA was phenyl-
ephrine (68; 40%), followed by ephedrine (41; 24%).
Discussion
This survey of 1067 anaesthetists from the UK, AUS/NZ
and the USA reveals important differences in practice
with regards to intraoperative fluid therapy and GDFT
specifically. The response rates were moderate or low,
especially in the USA, and it is likely that the present
data represents views of a self-selected group among the
anaesthetists who were randomly invited to participate.
Such selection could be based on strong positive or
negative views on GDFT. Nevertheless, certain
observations can be made and hypotheses generated
regarding the interest in and barriers to GDFT in the
UK and AUS/NZ. The poor response rate from the USA
limits the validity of any statements regarding practiceTable 4 Situations when goal-directed fluid therapy is
used
Indication (%) AUS/NZ (n = 87) UK (n = 523)
Major Surgery 50 (69) 326 (73)
Significant Comorbidities 51 (70) 367 (83)
Specific Operations 20 (27) 107 (24)
Instrument availability 19 (26) 125 (28)
Random 0 11 (3)in this region except to speculate that there is compara-
tively lesser interest in this topic.
The use of GDFT seems to be significantly less prevalent
in AUS/NZ compared to the UK amongst respondents in
this survey. The majority of the respondents were involved
in major abdominal surgery and orthopaedic surgery and
used GDFT in patients with significant comorbidities. The
ODM is the most commonly utilised instrument in the UK
with significant variation in preferences in other regions.
The most significant barriers to conducting GDFT were ei-
ther a lack of availability of monitoring tools or a lack of
experience with instruments. Even though a proportion of
respondents from all regions remain unconvinced of the
benefits of GDFT, there was significant enthusiasm overall
towards trialling GDFT if barriers were to be removed.
The use of GDFT was most common in the UK which
may have been made possible by governmental endorse-
ment and funding of the ODM specifically with demon-
strated cost-effectiveness [15,16]. Nationally-driven imple-
mentation may also potentially overcome the problems
associated with silo budgeting as GDFT represents an
anaesthetic intervention- thereby adding cost to clinical
departments of anaesthesia- to provide financial benefits
for surgical services such as decreased hospital length
of stay. This represents a potential blueprint for other
regions to follow. For clinicians, the recently published
GIFTASUP guidelines which recommend mandatory use
of GDFT in major abdominal surgery may have also
provided further impetus [20].
Moreover, a significant portion of the evidence sup-
porting GDFT originates from the UK [9,11,29]. The re-
cent guidelines from the European Enhanced Recovery
After Surgery (ERAS) group have also shown enthusiasm
towards GDFT and the ODM and, as ERAS protocols
are instituted across the UK, GDFT has been integrated
into practice as well [19,30,31]. This has likely led to the
emergence of the ODM as the preferred tool to conduct
GDFT in the UK. In contrast, the principles of optimised
perioperative care have shown reduced penetrance in











Figure 2 Would you like to use Goal-Directed Fluid Therapy? (Columns from left to right respectively: Yes/No/Undecided).
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ference with regards to tools for GDFT.
The barriers identified to the use of GDFT appear emi-
nently solvable especially if the observed benefits from
trials are replicated in clinical practice [13]. Many of the
instruments used to conduct GDFT are simple to use and
the learning curve for the ODM can be overcome after 12
insertions [34]. However, it should be noted that in the
context of abdominal surgery, restrictive fluid regimens
have also shown similar benefits to GDFT and the majority
of the trials investigating GDFT have not been conducted
in an environment of standardised, optimised perioperative
care [14,23].
A proportion of people from all the regions surveyed re-
main sceptical regarding the proposed benefits of GDFT.
To an extent, this is justified as important questions re-
main unanswered, such as efficacy in settings where fluid
restriction has been shown to be beneficial [21-23]. None-
theless, it is interesting to note that in the absence of
barriers, a high proportion of respondents would be will-
ing to consider GDFT into their practice. This suggests
that future randomised trials or selective clinical imple-
mentation of GDFT remain feasible and are required.
Whilst the use of intraoperative crystalloids was largely
homogeneous between the regions, there were interesting
differences in practice between the three regions with
regards to colloid use. There are considerable differ-
ences between individual classes of colloids as well as
between the individual colloid products themselves
[35,36]. Succinylated gelatin solutions were favoured in
the UK and AUS/NZ with the latter showing a wide
variation in practice. This may be a reflection of the
variable availability and cost of these solutions.
There are important limitations to this study which
need to be considered alongside the results. The surveywas designed on the basis of questions of clinical im-
portance but was not developed with a focus group nor
with redundant questions to validate its methodology.
Moreover, since the survey aimed towards an overview
of GDFT, specifics could not be elucidated regarding any
one aspect (e.g. specific barriers). Any barriers identified
were the opinion of the respondent and may not be re-
flective of the institution or the region in its entirety.
The number of individuals to be surveyed was limited by
the respective professional associations. The colleges
facilitated selection of individuals with no author input
allowed regarding this. The only selection criterion was
to prevent administration of the survey to individuals
who had previously replied to other college-led surveys
to minimise responder fatigue. In the context of a low-
moderate response rate, it cannot be assumed with cer-
tainty that it is representative of the anaesthetic commu-
nity in its entirety.
Conclusion
There are important differences in fluid administration
and the use of GDFT between anaesthetists from the
UK and AUS/NZ. The identified barriers can potentially
be overcome and though some clinicians remain uncon-
vinced, there is significant interest in utilising GDFT in
clinical practice. Future directions from this work can
include selective implementation of GDFT or further
clinical studies.
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